Literature DB >> 1150819

Determination of perphenazine and its sulphoxide metabolite in human plasma after therapeutic doses by gas chromatography.

N E Larsen, J Naestoft.   

Abstract

A gas chromatographic method for the determination of perphenazine (Tri-lafon) and its main metabolite in human plasma, perphenazine sulphoxide, has been developed. The procedure involves the use of an electron capture detector and permits the determination of the drug and its metabolite at concentrations down to 0.2 mug/l. This is sufficient for analyzing plasma from patients on ordinary treatment with perphenazine. Tests for specificity revealed no interference by nortriptyline or biperidine.

Entities:  

Mesh：

Substances：

Year:  1975        PMID： 1150819     DOI： 10.1016/s0021-9673(01)91797-2

Source DB:  PubMed          Journal:  J Chromatogr


  9 in total

Review 1.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

2.  Gas chromatographic - mass spectrometric determination of dixyrazine in human blood.

Authors:  G Brante; S Jönsson; A Melander
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  Effects of perphenazine enanthate injections on prolactin levels in plasma from schizophrenic women and men.

Authors:  H Lindholm; B Gullberg; A Ohman; G Sedvall
Journal:  Psychopharmacology (Berl)       Date:  1978-04-14       Impact factor: 4.530

4.  Clinical pharmacokinetic studies of perphenazine.

Authors:  C Eggert Hansen; T Rosted Christensen; J Elley; L Bolvig Hansen; P Kragh-Sorensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  Plasma levels of perphenazine and its major metabolites during simultaneous treatment with anticholinergic drugs.

Authors:  L B Hansen; J Elley; T R Christensen; N E Larsen; J Naestoft; E F Hvidberg
Journal:  Br J Clin Pharmacol       Date:  1979-01       Impact factor: 4.335

6.  Plasma concentrations of perphenazine and its sulphoxide metabolite during continuous oral treatment.

Authors:  L B Hansen; N E Larsen
Journal:  Psychopharmacology (Berl)       Date:  1977-07-18       Impact factor: 4.530

7.  Plasma levels of perphenazine (Trilafon) related to development of extrapyramidal side effects.

Authors:  L B Hansen; N E Larsen; P Vestergård
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

8.  Dose-response relationships of perphenazine in the treatment of acute psychoses.

Authors:  L B Hansen; N E Larsen; N Gulmann
Journal:  Psychopharmacology (Berl)       Date:  1982       Impact factor: 4.530

9.  Radioimmunoassay for perphenazine in human plasma.

Authors:  K K Midha; C Mackonka; J K Cooper; J W Hubbard; P K Yeung
Journal:  Br J Clin Pharmacol       Date:  1981-01       Impact factor: 4.335
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.